Table 1.
Baseline patient characteristics for the PANTS RNA-seq subcohort.
| Adalimumab [ADA] | Infliximab [IFX] | Drugs pooled | p-value | |
|---|---|---|---|---|
| Sex [Col %] | ||||
| Female | 78 [48.4%] | 89 [54.6%] | 167 [51.5%] | |
| Male | 83 [51.6%] | 74 [45.4%] | 157 [48.5%] | |
| Age of onset [years] | 0.774 | |||
| Mean [SD] | 33.3 [15.4] | 32.8 [15.3] | 33.1 [15.3] | Wilcoxon rank-sum |
| Missing | 0 | 0 | 0 | |
| Disease duration [years] | 0.546 | |||
| Mean [SD] | 6.1 [8.1] | 5.9 [7.7] | 6.0 [7.9] | Wilcoxon rank-sum |
| Missing | 0 | 0 | 0 | |
| Smoking status [Col %] | 0.263 | |||
| Current | 28 [17.4%] | 36 [22.1%] | 64 [19.8%] | Fisher exact |
| Ex | 55 [34.2%] | 43 [26.4%] | 98 [30.2%] | |
| Never | 78 [48.4%] | 84 [51.5%] | 162 [50.0%] | |
| Crohn’s-related surgery [Col %] | 0.549 | |||
| No | 114 [70.8%] | 110 [67.5%] | 224 [69.1%] | Fisher exact |
| Yes | 47 [29.2%] | 53 [32.5%] | 100 [30.9%] | |
| On immunomodulator ever [Col %] | 0.543 | |||
| No | 23 [14.3%] | 28 [17.2%] | 51 [15.7%] | Fisher exact |
| Yes | 138 [85.7%] | 135 [82.8%] | 273 [84.3%] | |
| On immunomodulator at baseline [Col %] | 0.912 | |||
| No | 79 [49.1%] | 81 [49.7%] | 160 [49.4%] | Fisher exact |
| Yes | 82 [50.9%] | 82 [50.3%] | 164 [50.6%] | |
| On corticosteroids at baseline [Col %] | 0.011 | |||
| No | 113 [70.2%] | 92 [56.4%] | 205 [63.3%] | Fisher exact |
| Yes | 48 [29.8%] | 71 [43.6%] | 119 [36.7%] | |
| Baseline BMI | 0.237 | |||
| Mean [SD] | 25.2 [6.2] | 24.3 [5.5] | 24.8 [5.9] | Wilcoxon rank-sum |
| Missing | 0 | 0 | 0 | |
| Primary response status [Col %] | 0.263 | |||
| Primary non-response | 76 [47.2%] | 66 [40.5%] | 142 [43.8%] | Fisher exact |
| Primary response | 85 [52.8%] | 97 [59.5%] | 182 [56.2%] | |
| CD8+ T cell [%] | 0.380 | |||
| Mean [SD] | 2.8 [4.2] | 2.8 [5.2] | 2.8 [4.7] | Wilcoxon rank-sum |
| Missing | 38 | 18 | 56 | |
| CD4+ T cell [%] | 0.752 | |||
| Mean [SD] | 9.2 [6.3] | 9.2 [6.8] | 9.2 [6.5] | Wilcoxon rank-sum |
| Missing | 38 | 18 | 56 | |
| B cell [%] | 0.094 | |||
| Mean [SD] | 1.9 [2.0] | 1.5 [1.9] | 1.7 [1.9] | Wilcoxon rank-sum |
| Missing | 38 | 18 | 56 | |
| Monocyte [%] | 0.497 | |||
| Mean [SD] | 8.9 [3.5] | 9.2 [3.7] | 9.0 [3.6] | Wilcoxon rank-sum |
| Missing | 38 | 18 | 56 | |
| NK cell [%] | 0.683 | |||
| Mean [SD] | 1.9 [3.2] | 1.9 [3.8] | 1.9 [3.5] | Wilcoxon rank-sum |
| Missing | 38 | 18 | 56 | |
| Granulocyte [%] | 0.911 | |||
| Mean [SD] | 74.3 [9.7] | 74.3 [10.8] | 74.3 [10.3] | Wilcoxon rank-sum |
| Missing | 38 | 18 | 56 |
Patient characteristics are stratified by drug subgroup. Values shown are count and percentage for categorical variables, and mean and standard deviation for continuous variables. Nominal p-values are reported for the comparison between drug subgroups.